Monday, December 12, 2016

ApoGen Biotechnologies Wins $7M

Seattle-based ApoGen Biotechnologies, a startup developing a new class of drugs for cancer therapy, has raised $7M in a Series A investment round. The funding came from Accelerator Corporation, AbbVie Ventures, Alexandria Venture Investments, ARCH Venture Partners, Eli Lilly and Company, Johnson & Johnson Innovation – JJDC, Inc., Watson Fund, L.P., WRF Capital and WuXi PharmaTech. The company says it is developing developing a new class of drugs that target the underlying mechanisms that cause genomic mutations to interrupt the development of drug resistance by cancer cells. The startup's technology is based on research out of the University of Minnesota. More information »